Genetic and pharmacological antagonism of NK1 receptor prevents opiate abuse potential
Autor: | Aubin Moutal, Todd W. Vanderah, Rajesh Khanna, Tally M. Largent-Milnes, Alexander J. Sandweiss, R Davidson-Knapp, Victor J. Hruby, Jackie Hu, Mary I. McIntosh, Aswini Kumar Giri, Takashi Yamamoto |
---|---|
Rok vydání: | 2017 |
Předmět: |
0301 basic medicine
media_common.quotation_subject Analgesic Substance P Pharmacology 03 medical and health sciences Cellular and Molecular Neuroscience chemistry.chemical_compound 0302 clinical medicine mental disorders Tachykinin receptor 1 medicine Molecular Biology media_common Addiction Dopaminergic Ventral tegmental area Psychiatry and Mental health 030104 developmental biology medicine.anatomical_structure nervous system Opioid chemistry Opiate Psychology 030217 neurology & neurosurgery medicine.drug |
Zdroj: | Molecular Psychiatry. 23:1745-1755 |
ISSN: | 1476-5578 1359-4184 |
DOI: | 10.1038/mp.2017.102 |
Popis: | Development of an efficacious, non-addicting analgesic has been challenging. Discovery of novel mechanisms underlying addiction may present a solution. Here we target the neurokinin system, which is involved in both pain and addiction. Morphine exerts its rewarding actions, at least in part, by inhibiting GABAergic input onto substance P (SP) neurons in the ventral tegmental area (VTA), subsequently increasing SP release onto dopaminergic neurons. Genome editing of the neurokinin 1 receptor (NK1R) in the VTA renders morphine non-rewarding. Complementing our genetic approach, we demonstrate utility of a bivalent pharmacophore with dual activity as a μ/δ opioid agonist and NK1R antagonist in inhibiting nociception in an animal model of acute pain while lacking any positive reinforcement. These data indicate that dual targeting of the dopaminergic reward circuitry and pain pathways with a multifunctional opioid agonist-NK1R antagonist may be an efficacious strategy in developing future analgesics that lack abuse potential. |
Databáze: | OpenAIRE |
Externí odkaz: |